Erythropoietin therapy: need for rationality and active surveillance.
Cazzola
Mario
M
University of Pavia Medical School, Division of Hematology, IRCCS Policlinico S. Matteo, Pavia, Italy. mario.cazzola@unipv.it
D000740:Anemia / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D001327:Autoimmune Diseases / Q000139:chemically induced / Q000175:diagnosis; D002986:Clinical Trials as Topic; D004300:Doping in Sports; D004921:Erythropoietin / Q000009:adverse effects / Q000096:biosynthesis / Q000172:deficiency / Q000627:therapeutic use*; D006801:Humans; D007674:Kidney Diseases / Q000150:complications; D009190:Myelodysplastic Syndromes / Q000150:complications; D009369:Neoplasms / Q000150:complications; D011994:Recombinant Proteins; D012010:Red-Cell Aplasia, Pure / Q000139:chemically induced / Q000175:diagnosis; D016896:Treatment Outcome; D014511:Uremia / Q000150:complications
D011994:Recombinant Proteins; D004921:Erythropoietin